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Polycystic ovary syndrome (PCOS) is a state of altered steroid hormone production and activity. Chronic estrogen
exposure or lack of progesterone due to ovarian dysfunction can result in endometrial hyperplasia and carcinoma.
A key contributor to our understanding of progesterone as a critical regulator for normal uterine function has been
the elucidation of progesterone receptor (PR) expression, regulation, and signaling pathways. Several human studies
indicate that PR-mediated signaling pathways in the nucleus are associated with progesterone resistance in women
with PCOS. The aim of this review is to provide an overview of endometrial progesterone resistance in women with
PCOS; to present the PR structure, its different isoforms, and their expression in the endometrium; to illustrate the
possible regulation of PR and PR-mediated signaling in progesterone resistance in women with PCOS; and to
discuss current clinical treatments for atypical endometrial hyperplasia and endometrial carcinoma in women with
PCOS and accompanying progesterone resistance.
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Polycystic ovary syndrome: a multifactorial disease
Polycystic ovary syndrome (PCOS) is a heterogeneous
hormone-imbalance disorder [1] that occurs in approxi-
mately 4% or 18% of reproductive-aged women worldwide
[2]. Although PCOS is usually diagnosed during the early
reproductive years, the precise etiology and pathogenesis
of PCOS remain uncertain. The main clinical complica-
tions of this disease include hyperandrogenism, chronic
oligo/anovulation, polycystic ovaries, insulin resistance,
and type 2 diabetes mellitus [1,3]. Because the signs and
symptoms of PCOS can vary among individuals, and be-
cause no single factor is likely to explain the constellation
of abnormalities in this syndrome, it is often difficult to ac-
curately diagnose women with PCOS. According to the
Rotterdam criteria provided by the American Society for
Reproductive Medicine and the European Society for
Human Reproduction and Embryology [4], at least two of
the following diagnostic criteria should be met: oligo/ano-
vulation; clinical signs of hyperandrogenism (e.g., hirsutism
and acne) and/or biochemical measurements; or enhanced
polycystic ovaries and/or multiple discrete follicles in diam-
eter in one ovary as detected by ultrasonography. In* Correspondence: ruijin.shao@fysiologi.gu.se
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stated.addition, other androgen excess disorders and specific eti-
ologies such as congenital adrenal hyperplasia, Cushing’s
syndrome, thyroid hormone abnormalities, hyperprolacti-
nemia, and ovarian/adrenal tumors need to be excluded.
In clinical practice, 75% of women with PCOS suffer
from anovulation infertility [5] and 50% of them experi-
ence recurrent pregnancy loss [6]. It is, however, not clear
whether these defects are caused by uterine dysfunction it-
self or by the interrupted interaction between uterine cells
and the developing embryo. Additionally, the chronic ano-
vulation seen in PCOS implies prolonged estrogen excess
or lack of progesterone and results in atypical endometrial
hyperplasia, which is the precursor of endometrial carcin-
oma [7,8]. Indeed, young women with PCOS-induced
endometrial hyperplasia are more likely than non-PCOS
women to develop endometrial carcinoma [9]. Therefore,
it is important to understand the mechanisms and conse-
quences behind the pathophysiological changes in the
endometrium in women with PCOS in order to develop
effective treatments to prevent the development of endo-
metrial carcinoma.
This review focuses on progesterone activity in the
endometrium and the structural characteristics of hu-
man progesterone receptor (PR) isoforms. The review
further compares PR isoform expression and regulation
in women with PCOS in relation to the clinical conse-
quences of progesterone resistance. We also discuss thehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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improve progesterone sensitivity in women with PCOS.
Review
Endometrial progesterone resistance
Progesterone is a key steroid hormone produced mainly
by the ovaries, and its synthesis and secretion are primar-
ily regulated by luteinizing hormone during the menstrual
cycle and by human chorionic gonadotropin during preg-
nancy [10]. Progesterone is absolutely required for uterine
implantation, decidualization, and maintenance of preg-
nancy [11]. The uterine endometrium includes epithelial
cells, stromal cells, immune cells, and blood vessels [12],
and both epithelial and stromal cells are exquisitely sensi-
tive to steroid hormone stimulation in women during
the menstrual cycle [13]. For example, 17ß-estradiol (E2)
drives epithelial cell proliferation whereas progesterone in-
hibits E2-stimulated epithelial cell proliferation [10].
Progesterone resistance implies a decreased responsive-
ness of target tissue to bioavailable progesterone [14], and
such an impaired progesterone response is seen in the
endometrium of women with PCOS [15,16]. Women with
PCOS often present with an abnormal menstrual cycle
and anovulation, and this results in minimal or absent P4
production as evidenced by the fact that the endometrium
is thicker in women with PCOS than in healthy women
[17]. In the literature, progesterone resistance generally re-
fers to women who suffer from endometriosis. Endometri-
osis is an E2-dependent disease but it alters a subset of
progesterone-regulated genes and pathways in the endo-
metrium [18]. Although gene expression analysis of PCOS
endometrium reveals progesterone resistance and candi-
date susceptibility genes in women with PCOS [16,19], the
molecular mechanisms underlying endometrial progester-
one resistance or sensitivity in these patients are not com-
pletely understood.
Current understanding of progesterone receptors
PRs mediate both genomic and non-genomic signaling
pathways. Uterine responsiveness to progesterone is
dependent on nuclear PR, which is a member of the
steroid receptor superfamily and regulates transcription
of target genes [11,18]. Like other steroid hormone re-
ceptors, PR is composed of a variable N-terminal transacti-
vation domain, a highly conserved DNA-binding domain, a
hinge domain, and a ligand-binding domain [20] (Figure 1).
In the absence of an activated ligand, PR is inactivated
through association with various heat shock proteins (hsp),
including hsp90, hsp70, and hsp40, and other co-repressor
proteins [10]. Ligand binding causes release of the multiple
hsp-subunit complex and the PR undergoes a conform-
ational change that allows the receptor dimer to interact
with specific progesterone response elements located within
the regulatory regions of its target genes [20] (Figure 2).There are two predominant isoforms of the PR, PRA and
PRB [10]. Both are encoded from the same PR gene
through the use of alternative promoters and translation
start sites. PRA lacks the N-terminal 164 aa of PRB [21]
(Figure 1). Importantly, the two PR isoforms are not func-
tionally equivalent, and in vitro experiments show that
PRA functions as a transcriptional inhibitor of PRB when
PRA and PRB are co-expressed [21]. In vivo knockout stud-
ies reveal that mice specifically lacking uterine PRA but not
PRB fail to display progesterone-induced inhibition of
E2-induced cell proliferation and that this results in uterine
dysfunction and infertility [22]. These animal studies sug-
gest that PRA might play a pivotal role in uterine function.
Both PRA and PRB can either homodimerize or hetero-
dimerize in vivo [23], and the relative expression of the
two isoforms varies dramatically in different tissues, cell
types, physiological states, and in diseases [10,20]. To date,
there is no evidence of distinct nuclear PR isoform expres-
sion linked to human endometrial function in vivo. Thus,
one should keep in mind that the relative contribution of
PRA and PRB might contribute to the diverse and indis-
pensable actions of progesterone in cellular events in
humans [24]. Furthermore, nuclear PRs exist in additional
isoforms each with varying intracellular domains (Figure 1).
Although PRC, PRM, and PRS have been identified in
human myometrial cells in vitro [25,26], the essential role
of these PR isoforms in the uterus in vivo is unknown.
Progesterone also acts through different membrane-
bound PRs that mediate non-genomic activities [27]
(Figure 2). Although the membrane-bound PRs appear
to be expressed and regulated in normal human endo-
metrium in a cycle-dependent manner [28], the precise
mechanisms of each membrane PR in the endometrial
cells remains to be determined.
In addition to the genomic and non-genomic effects of
progesterone, progesterone-independent mechanisms of
nuclear PR activation have been demonstrated in mouse
uterine tissues [29].
Comparison of nuclear PRA and PRB between normal and
PCOS endometria
PRA and PRB are both expressed in the epithelial and
stromal cells of the human endometrium [13], and the
levels of PRA and PRB expression fluctuate in the cycling
endometrium in an isoform-specific and cell-specific man-
ner [30,31] (Figure 3). During the proliferative phase, PRA
expression increases at the same rate as PRB in epithelial
cells but PRA expression is greater than PRB expression
in stromal cells [30,32]. During the secretory phase, how-
ever, PRA expression is decreased in epithelial cells [30,31]
but there is only minimal or no change in PRA expression
in stromal cells [30,32] (Figure 3). Furthermore, the level
of PRB expression is decreased in both epithelial and stro-
mal cells in the secretory phase [30,31]. These data suggest
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Figure 1 The general structure of human progesterone receptors. The PR protein consists of four structurally and functionally distinct
domains: the N-terminal transactivation domain (NTD), the DNA binding domain (DBD), a small hinge region, and the C-terminal ligand-binding
domain (LBD). The LBD shares the greatest degree of homology among the different human PR isoforms. In addition to hPRA and hPRB, hPRC
lacks the first of two zinc fingers and be defective in DNA binding, whereas hPRM lacks both NTD and DBD. The structure of both hPRC and
hPRM predicts extra-nuclear localization. hPRS contains only LBD and may be involved in the progesterone-induced nuclear translocation. hPR,












Figure 2 Progesterone receptors mediate genomic and
non-genomic actions in human endometrium. Uterine
responsiveness to progesterone is dependent on nuclear PRA/B.
Progesterone also acts through different membrane-bound PRs that
mediate non-genomic activities. In addition to progesterone, nuclear
PRA/B has been shown to be under estrogenic control in human and
animal uteri. Although the non-genomic effects of membrane-bound
PRs in the endometrium are unclear, several studies have suggested that
the PRA/B-regulated genes are involved in the regulation of endometrial
proliferation. PRA/B, progesterone receptor isoforms A and B.
Li et al. Journal of Biomedical Science 2014, 21:2 Page 3 of 7
http://www.jbiomedsci.com/content/21/1/2that there are different sensitivities of PRA and PRB to the
effects of progesterone in stromal cells. As a result of nu-
clear PRA- and PRB-specific functional differences [4], it
is reasonable to speculate that the way in which human
endometrial cells respond to progesterone in vivo might
be determined by changes not only in the expression of
the individual nuclear PR isoforms but also by ratio of
PRA to PRB.
It has been reported that endometrial responsiveness to
progesterone is reduced in women with PCOS [15,16], and
a previous study has shown that total endometrial PR ex-
pression is higher in women with PCOS who have anovu-
lation compared to women with PCOS who still ovulate
[33]. Moreover, the increased PR expression in epithelial
cells is greater than that in stromal cells in women with
PCOS [34] suggesting that lower binding of progesterone
in stromal cells could lead to the promotion of E2-induced
epithelial cell proliferation in women with PCOS. The
in vivo manipulation of the functional consequence of indi-
vidual PR isoforms under physiological and pathological
conditions in human endometrium is difficult if not impos-
sible. However, because the PR-mediated responses depend
on the coordinated, opposing, and compensatory functions
of PRA and PRB [20,21], whether one isoform is more im-
portant than the other in PCOS women with progesterone
resistance requires further study.
PR-mediated signaling in endometrial progesterone
resistance: the role of stromal cells
In vitro animal studies indicate that functional stromal
cells are required for epithelial cell proliferation and differ-
entiation in the uterus [12]. It is unclear, however, whether
human endometrium has a similar paracrine regulatory
interaction as seen in the uterine endometrium in animal
models. PRB has been postulated to function as an anti-
proliferative regulator in stromal cells, and the knockdown
of PRB is reported to increase the proliferation of humanendometrial stromal cells in vitro [35]. Interestingly, an in-
crease in total PR expression [34] is associated with de-
creased expression of ki-67 (a nuclear protein that is
necessary for cellular proliferation) in endometrial stromal
cells in women with PCOS [19]. Although the effect of up-
regulation of specific PR isoforms in women with PCOS is
not clear (Figure 3), it is reasonable to hypothesize that lack
of P4-induced, PR-mediated stromal cell proliferation could
be a cause of progesterone resistance in women with
PCOS. In addition to progesterone, nuclear PR isoforms
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Figure 3 Summary of progesterone receptor isoform expression and regulation in normal and PCOS women. PRA and PRB are both
expressed in the epithelial and stromal cells of the human endometrium, and the levels of PRA and PRB expression fluctuate in the cycling
endometrium in an isoform-specific and cell-specific manner. Several studies have shown that the endometrial PR expression is altered in women
with PCOS. See text for details. The normal endometrium is stained with hematoxylin and eosin. PR, progesterone receptor; Epi, epithelial cells;
Str, stromal cells. See text for details.
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one in females, and activation of the two estrogen receptors
(ERα and ERβ) plays a pivotal role in the regulation of uter-
ine function under both physiological and pathological con-
ditions [29,36]. In vivo and in vitro animal studies [11] have
shown that ERβ is the dominant ER in uterine stromal cells
[37] and that ERβ is necessary to inhibit E2-induced epithe-
lial cell proliferation [12]. These results suggest that stromal
PR and ERβ have the same inhibitory effect on epithelial
cell proliferation.
The endometrium from PCOS women with progesterone
resistance often displays endometrial hyper-proliferation
[8]. PRB has been shown to physically associate with ERβ
in rat uterine stromal cells [38], and it has been shown that
treatment with E2 induces PRB expression more than PRA
expression in human endometrium [39]. Although in-
creased PR expression [34] and decreased ERβ expressionare seen in women with PCOS compared to controls [40],
how epithelial cell proliferation is regulated in vivo by the
coordinated interaction of stromal PR and ERβ in women
with PCOS has yet to be determined.
Although the individual roles of PRA and PRB in the
uterus have been confirmed by knockout mouse studies
[22], it is not completely understood how PR-mediated
gene expression in epithelial and stromal cells is regulated
in the human endometrium under pathological conditions
in vivo. However, differential changes in gene expression
in the endometrium have been shown to be associated
with the onset of PCOS in women [19] with progesterone
resistance [16]. One intriguing finding is that the alter-
ations in many PR-related genes are evident in women
with endometriosis and accompanying progesterone re-
sistance [41], but there are not many genes changed in
women with PCOS and accompanying progesterone
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related mitogen-inducible gene 6 is observed in both
endometriosis and PCOS [16,41], different levels of regula-
tion of PR-related transforming growth factor β-1 is found
between women with PCOS [19] and those with endomet-
riosis [41]. Although there is conflicting reports regarding
the PR-regulated MUC1expression in women with PCOS
and uterine receptivity [33,34], we suspect that the differ-
ent PR-related gene expression profiles between women
with PCOS [33,34] and endometriosis [42] could be re-
lated to differences in PR isoform expression.
Clinical perspectives
Treatment with progesterone appears to reverse endomet-
rial hyperplasia in women [43], and PR-knockout mice
treated with E2 develop severe uterine hyperplasia [22].
Endocrine and metabolic abnormalities that are left un-
treated in women with PCOS often develop into atypical
endometrial hyperplasia and endometrial dysfunction-
induced infertility [8]. Although progesterone-based oral
contraceptive therapy is often efficacious [44], approxi-
mately 30% of women with PCOS fail to respond to such
treatment [45] and progress to the development of atypical
hyperplasia and further transformation to endometrial
cancer. Recently, animal studies demonstrating the stro-
mal PR-dependent antitumor effects provide a mechanis-
tic link between progesterone action and endometrial
dysfunction, in particular the development of endometrial
carcinoma [46]. Therefore, loss of stromal progesterone-
PR signaling in the endometrium in women with PCOS
might be one of causal factors in the development of atyp-
ical endometrial hyperplasia and endometrial carcinoma
[12,15].
In addition, women with PCOS often display both in-
sulin resistance and reduced insulin responsiveness. Our
laboratory and others have previously shown that the
combination of metformin (N,N-dimethylbiguanide) and
oral contraceptives are sufficient to reverse atypical
endometrial hyperplasia in women with PCOS and to re-
verse insulin resistance in order to preserve their fertility
[15,47]. Recently, we reported that the combined treat-
ment with metformin and oral contraceptives are cap-
able of reverting early endometrial carcinoma to normal
endometria in addition to improving hyperandrogenemia
and insulin resistance in PCOS women with progester-
one resistance (Li et al., in submission). An important
unanswered question is what links progesterone-PR sig-
naling to atypical endometrial hyperplasia in PCOS
women with progesterone resistance.
Conclusion
The elevated estrogen and progesterone levels in women
during the luteal phase of the menstrual cycle and during
normal pregnancy are associated with reduced insulinsensitivity [48]. These findings suggest a potential link be-
tween the activation of steroid receptor signaling and insu-
lin resistance. Combined treatment with metformin and
Diane-35 might provide the beneficial effects on proges-
terone and insulin resistance as well as reverting early
endometrial carcinoma, but knowledge about how their
co-effects are exerted is limited. We note that the absence
of progesterone action or an imbalance between E2 and
progesterone allows E2 to induce oncogenesis [12], and
progesterone resistance is associated with insulin resist-
ance and dysregulation of endometrial stromal PR activity
[45]. It has been reported that either one or both of PRA
and PRB expression is decreased in women with endomet-
rial carcinoma compared to those with normal endomet-
rium [49]. Moreover, treatment with metformin not only
inhibits P450 aromatase activation and suppresses endo-
metrial cell proliferation [50], but it also reduce progester-
one resistance and increases PR expression in endometrial
cancer cells [51,52]. Therefore, a possible scenario is that
endometrial cells coexpress receptors for insulin/insulin-
like growth factor-1 (IGF-1) [53-56] and progesterone/E2
[31,57] and that metformin and Diane-35 coordinate the
regulation of insulin/IGF-1 receptor, PR, and ER levels.
This would result in a significant increase in the number
of receptor molecules available for signaling in the endo-
metrium in PCOS women with progesterone resistance.
How a positive effect of metformin combined with Diane-
35 at the molecular level could inhibit the development of
atypical endometrial hyperplasia and endometrial carcin-
oma is a matter for further investigation. We believe that
identifying undiscovered mechanistic pathways in the
endometrium from PCOS women with both progesterone
and insulin resistance remains an attractive research ap-
proach to understanding the pathogenesis of atypical
endometrial hyperplasia and endometrial carcinoma.
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